Search results
For over 35 years Parexel has been a trusted global CRO and biopharmaceutical services company. Learn more about how we can help.
- Careers
Transform healthcare, trial new treatments, and reinvent...
- 日本
Parexel...
- Contact Us
Need to expedite your development journey? Parexel is here...
- Biotech Solutions
At Parexel Biotech, we’ve integrated our wide breadth of...
- Volunteer
(Xoli Belgrave): For us here at Parexel, the involvement of...
- Early Development and Innovation
At Parexel, we’re perfectly positioned with fully integrated...
- FSP Delivery Models
At Parexel, we're very proud that our FSP partnerships are...
- Integrated Clinical Development
Engage the people who matter most. At Parexel, we combine a...
- Careers
Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help lifesaving treatments reach patients faster.
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients...
Whatever the size of your biopharmaceutical company, our global presence can help accelerate your drug development around the world. Our diverse professionals represent the best and the brightest in clinical, regulatory and market access specialties.
Firma Parexel, wiodący dostawca rozwiązań wspierających rozwój innowacyjnych opcji terapeutycznych przyczyniających się do poprawy zdrowia na świecie, ogłosiła zawarcie nowej umowy ramowej dotyczącej świadczenia usług z farmaceutycznym koncernem Pfizer Inc. Umowa stanowi kontynuację trwającej dekadę współpracy obu firm i jest ...
2 lip 2021 · BOSTON and Durham, N.C. July 2, 2021 — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (“EQT Private Equity”) and the ...
